Calluna Pharma AS, a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory and ...
Promising data show a median overall survival of 18.6 months, with 40% of patients alive at 2 years.Results suggest that nuclear GSK-3β ...
The combination was well tolerated: no treatment-related deaths occurred, and only 6% (2 patients) were discontinued due to ...
hubXchange’s Antibody Therapeutics Xchange Boston 2026 brings together senior-level scientists, R&D leaders, and executives ...
Motif ? one of the clinical trial technology market's fastest growing companies ? continues contributing to major innovations in how clinical trial patient data are collected, with Chief Scientific ...
We found that one-third of pharmaceutical companies proactively released the launch price of their medications between 2022 and 2024, and another third released them reactively. Smaller public ...
New Jersey’s Innovation Evergreen Fund invests $6.2M in three startups to strengthen the state's innovation economy.
UK's health regulator on Monday approved GSK's twice-yearly drug for use as an add-on treatment for asthma in patients aged ...
Rival European pharma giants Sanofi and GSK have both forged new partnerships to bolster their preclinical research. | Rival ...
GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won an endorsement from ...
Akston Biosciences Corp., pet medicines company, has filed paperwork with the U.S. Securities and Exchange Commission to begin the initial public offering process.
The European Medicines Agency has recommended the approval of GSK's add-on drug to treat asthma and a chronic inflammatory sinus condition, the company said on Friday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback